Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KROS Keros Therapeutics	$13.73 +2.8%	$14.03	$9.12 ▼ $72.37	$557.71M	1.33	442,591 shs	716,794 shs
PHAT Phathom Pharmaceuticals	$9.74 +3.6%	$8.81	$2.21 ▼ $19.71	$690.96M	0.45	1.05 million shs	1.37 million shs
RLAY Relay Therapeutics	$3.22 -7.7%	$3.47	$1.77 ▼ $10.72	$555.16M	1.62	3.04 million shs	4.40 million shs
TIL Instil Bio	$27.99 +7.9%	$28.04	$9.85 ▼ $92.00	$183.61M	2.16	188,409 shs	120,462 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KROS Keros Therapeutics	0.00%	-4.12%	-4.92%	-0.07%	-69.74%
PHAT Phathom Pharmaceuticals	0.00%	+16.65%	+6.10%	+209.21%	-17.11%
RLAY Relay Therapeutics	0.00%	-4.17%	-10.56%	+3.54%	-51.94%
TIL Instil Bio	0.00%	+25.91%	+14.29%	+104.61%	+159.16%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KROS Keros Therapeutics	2.6638 of 5 stars	3.3	2.0	2.5	3.3	0.6
PHAT Phathom Pharmaceuticals	3.097 of 5 stars	3.5	2.0	1.6	5.0	0.6
RLAY Relay Therapeutics	1.9516 of 5 stars	3.5	0.0	2.2	2.5	0.6
TIL Instil Bio	2.1402 of 5 stars	3.5	2.0	0.0	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KROS Keros Therapeutics	2.50	Moderate Buy	$30.00	118.50% Upside
PHAT Phathom Pharmaceuticals	3.00	Buy	$17.50	79.67% Upside
RLAY Relay Therapeutics	2.92	Moderate Buy	$17.25	435.71% Upside
TIL Instil Bio	3.00	Buy	$119.00	325.15% Upside

Current Analyst Ratings Breakdown

Latest TIL, PHAT, KROS, and RLAY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	KROS Keros Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $20.00
8/8/2025	RLAY Relay Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Strong-Buy ➝ Strong-Buy	$29.00 ➝ $19.00
6/10/2025	KROS Keros Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$32.00 ➝ $18.00
6/9/2025	PHAT Phathom Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $17.00
6/9/2025	PHAT Phathom Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/6/2025	PHAT Phathom Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00
6/5/2025	TIL Instil Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$125.00 ➝ $125.00
6/2/2025	TIL Instil Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/30/2025	KROS Keros Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$15.00
5/22/2025	TIL Instil Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$110.00 ➝ $105.00
5/12/2025	KROS Keros Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$41.00 ➝ $26.00

(Data available from 8/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KROS Keros Therapeutics	$3.55M	157.10	N/A	N/A	$14.11 per share	0.97
PHAT Phathom Pharmaceuticals	$55.25M	12.51	N/A	N/A	($3.71) per share	-2.63
RLAY Relay Therapeutics	$10.01M	55.46	N/A	N/A	$4.65 per share	0.69
TIL Instil Bio	N/A	N/A	N/A	N/A	$25.96 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KROS Keros Therapeutics	-$187.35M	$0.31	44.29	N/A	1.80	8.06%	2.96%	2.74%	N/A
PHAT Phathom Pharmaceuticals	-$334.33M	-$4.73	N/A	N/A	N/A	-289.51%	N/A	-90.40%	N/A
RLAY Relay Therapeutics	-$337.71M	-$1.95	N/A	N/A	N/A	N/A	-41.49%	-37.43%	N/A
TIL Instil Bio	-$74.14M	-$11.97	N/A	N/A	N/A	N/A	-45.52%	-29.23%	8/12/2025 (Estimated)

Latest TIL, PHAT, KROS, and RLAY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	N/A	TIL Instil Bio	-$1.72	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	RLAY Relay Therapeutics	-$0.49	-$0.41	+$0.08	-$0.41	$0.07 million	$0.70 million
8/6/2025	Q2 2025	KROS Keros Therapeutics	-$1.14	-$0.76	+$0.38	-$0.76	$3.83 million	$0.02 million
5/13/2025	Q1 2025	TIL Instil Bio	-$2.02	-$4.32	-$2.30	-$4.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KROS Keros Therapeutics	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KROS Keros Therapeutics	N/A	21.11	21.11
PHAT Phathom Pharmaceuticals	N/A	2.38	2.35
RLAY Relay Therapeutics	N/A	20.92	20.92
TIL Instil Bio	0.58	30.33	30.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KROS Keros Therapeutics	71.56%
PHAT Phathom Pharmaceuticals	99.01%
RLAY Relay Therapeutics	96.98%
TIL Instil Bio	60.56%

Insider Ownership

Company	Insider Ownership
KROS Keros Therapeutics	22.90%
PHAT Phathom Pharmaceuticals	24.10%
RLAY Relay Therapeutics	4.32%
TIL Instil Bio	46.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KROS Keros Therapeutics	100	40.62 million	31.31 million	Optionable
PHAT Phathom Pharmaceuticals	110	70.94 million	53.85 million	Optionable
RLAY Relay Therapeutics	330	172.41 million	164.96 million	Optionable
TIL Instil Bio	410	6.56 million	3.51 million	No Data

TIL, PHAT, KROS, and RLAY Headlines

Recent News About These Companies

Instil Bio stock rises after positive data for cancer therapy in China

July 31, 2025 | za.investing.com

Instil's licensed PD-L1xVEGF bispecific shows promise in China, instilling hope for upcoming US test

July 31, 2025 | fiercebiotech.comF

ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China

July 31, 2025 | globenewswire.com

US FDA clears Instil Bio’s IND application for AXN-2510, a PD-L1xVEGF bispecific antibody, for a phase 1 trial in relapsed/refractory solid tumours

July 4, 2025 | pharmabiz.comP

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed ...

July 3, 2025 | manilatimes.netM

Instil Bio Announces FDA Clearance for IND of AXN-2510, Phase 1 Trial Expected by End of 2025 - Nasdaq

July 3, 2025 | nasdaq.com

Instil Bio Shares Climb After FDA Clears Tumor Treatment Application

July 2, 2025 | marketwatch.com

Instil Bio stock jumps after FDA clearance of IND application

July 2, 2025 | in.investing.com

Instil Bio Shares Surge on FDA Clearance for Investigational Cancer Therapy

July 2, 2025 | msn.com

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors

July 2, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/07/02/3109003/0/en/instil-bio-announces-u-s-f-d-a-clearance-of-investigational-new-drug-ind-application-for-axn-2510-a-pd-l1xvegf-bispecific-antibody-for-a-phase-1-trial-in-relapsed-refractory-solid-.html$

Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know

June 20, 2025 | zacks.com

Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet

June 16, 2025 | zacks.com

Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

June 11, 2025 | globenewswire.com

Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice

June 4, 2025 | zacks.com

Instil Bio appoints new Chief Medical Officer

June 4, 2025 | uk.investing.com

Instil Bio appoints Jamie Freedman as Chief Medical Officer

June 2, 2025 | msn.com

Instil Bio, Inc. Appoints Jamie Freedman, M.D., Ph.D., as Chief Medical Officer to Propel Cancer Therapy Development

June 2, 2025 | quiverquant.comQ

Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer

June 2, 2025 | globenewswire.com

Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference

May 30, 2025 | globenewswire.com

Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock?

May 29, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

The Bottom Is in for Kohl’s, But Let the Share Price Come to You
By Thomas Hughes | July 23, 2025
View The Bottom Is in for Kohl’s, But Let the Share Price Come to You
3 Stocks to Cushion Your Portfolio This Earnings Season
By Chris Markoch | July 16, 2025
View 3 Stocks to Cushion Your Portfolio This Earnings Season
Amazon's Earnings: What Comes Next and How to Play It
By Sam Quirke | August 1, 2025
View Amazon's Earnings: What Comes Next and How to Play It
Snap-On: Snap Up This Strong Signal While It’s Still Cheap
By Thomas Hughes | July 18, 2025
View Snap-On: Snap Up This Strong Signal While It’s Still Cheap
Figma's Wild IPO Ride: Is the Stock's Premium Price Justified?
By Jeffrey Neal Johnson | August 5, 2025
View Figma's Wild IPO Ride: Is the Stock's Premium Price Justified?

TIL, PHAT, KROS, and RLAY Company Descriptions

Keros Therapeutics NASDAQ:KROS

$13.73 +0.37 (+2.77%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$13.38 -0.35 (-2.55%)

As of 08/8/2025 07:00 PM Eastern

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Phathom Pharmaceuticals NASDAQ:PHAT

$9.74 +0.34 (+3.62%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$9.64 -0.10 (-0.99%)

As of 08/8/2025 07:00 PM Eastern

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Relay Therapeutics NASDAQ:RLAY

$3.22 -0.27 (-7.74%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$3.45 +0.23 (+7.14%)

As of 08/8/2025 07:34 PM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Instil Bio NASDAQ:TIL

$27.99 +2.05 (+7.90%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$27.53 -0.46 (-1.66%)

As of 08/8/2025 04:10 PM Eastern

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time